Nicholas A Flores
Nicholas A Flores
Pitavastatin (nisvastatin) is an HMG CoA reductase inhibitor being developed jointly by Nissan, Kowa Kogyo, Novartis and Sankyo for the potential treatment of atherosclerosis and hyperlipidemia.
Avasimibe Pfizer [0.03%]
阿伐他汀培泽公司
John R Burnett,Murray W Huff
John R Burnett
Avasimibe (also known as CI-1011 or PD-148515) is a selective acyl-coenzyme A:cholesterol O-acyltransferase (ACAT) inhibitory lipid-regulating agent under development by Pfizer (formerly Parke-Davis) for the potential treatment of hyperlipi...
S-18886 Servier [0.03%]
塞维药厂S-18886
Stavros K Kakkos,Andrew N Nicolaides
Stavros K Kakkos
S-18886, the active isomer of S-18204, is a thromboxane A2 receptor antagonist with a long duration of action. The compound is under development by Servier for the potential treatment of cardiovascular diseases [269611]. By 2000, a clinical...
Helena Gylling,Tatu A Miettinen
Helena Gylling
Statins effectively inhibit cholesterol synthesis and are currently the most commonly used drugs for the treatment of hypercholesterolemia. However, patients with familial hypercholesterolemia and those unwilling to take, or who cannot tole...
Thomas M A Bocan
Thomas M A Bocan
HMG-CoA reductase, in addition to being the rate-limiting enzyme in the cholesterol biosynthetic pathway, is involved in the regulation of receptors for low-density lipoprotein (LDL)-cholesterol. Clinical studies in men and women demonstrat...
Tacrolimus Fujisawa [0.03%]
富士胶片他克莫司
Andrew T Gewirtz,Shanthi V Sitaraman
Andrew T Gewirtz
Fujisawa has launched the immunosuppressant tacrolimus extensively for use in organ transplantation. The compound has also been developed for the treatment of atopic dermatitis, for which it has been launched in the US, Japan, Switzerland, ...
Srinivasan Ganesan,Simon P L Travis,Tariq Ahmad et al.
Srinivasan Ganesan et al.
Therapeutic options for patients with refractory ulcerative colitis or Crohn's disease have recently been augmented by the introduction of biological therapies. The pro-inflammatory cytokine, tumor necrosis factor (TNF)-alpha is present in ...
Srinivasan Ganesan,Simon P L Travis,Tariq Ahmad et al.
Srinivasan Ganesan et al.
Tumor necrosis factor-alpha (TNF alpha) is one of several pro-inflammatory cytokines that have been implicated in the pathogenesis of Crohn's disease (CD). Treatment with antibodies to TNF alpha has been shown to reduce mucosal inflammation...
GM-CSF treatment for Crohn's disease: a stimulating new therapy? [0.03%]
用于治疗克罗恩病的GM-CSF疗法：一种令人振奋的新疗法？
Jacque N Wilk,Joanne L Viney
Jacque N Wilk
Crohn's disease (CD) has been classically viewed as an overactive intestinal immune response to the normal constituents of the gut flora. Most therapeutic strategies to date have tried to suppress this overactive adaptive immune response. R...
The impact of beta-lactamases on the development of novel antimicrobial agents [0.03%]
β-内酰胺酶对新型抗菌药物研发的影响
Karen Bush
Karen Bush
beta-Lactamases have been critical factors for the selection and development of beta-lactam-containing antibacterial agents for almost 60 years. New agents under investigation continue to be evaluated based on their interactions with beta-l...